Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xeris Biopharma Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xeris Biopharma Holdings's regulatory disclosures and financial reporting.
Xeris Biopharma Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 172,625,762 common shares entitled to vote as of April 14, 2026, 128,268,073 were represented, establishing a quorum. Stockholders elected Class II directors Dawn Halkuff and John Johnson by plurality vote.
They also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers under the Say‑on‑Pay Vote. No other matters were submitted for stockholder action.
Xeris Biopharma Holdings officer Beth Hecht reported an open-market sale of Company stock. She sold 16,667 shares of common stock at a weighted average price of $6.0588 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, she continues to hold 1,176,506 shares directly.
Xeris Biopharma Holdings reported a strong turnaround for the quarter ended March 31, 2026, moving to net income of $2.2 million from a net loss of $9.2 million a year earlier. Total revenue rose to $83.1 million from $60.1 million, driven mainly by Recorlev.
Recorlev net product revenue nearly doubled to $49.8 million, while Gvoke was stable at $20.8 million and Keveyis grew modestly to $11.9 million. Cost of goods sold grew more slowly than revenue, improving gross margin. Operating income reached $7.9 million, supported by higher sales despite increased selling and R&D spending.
Xeris ended the quarter with cash, cash equivalents and restricted cash of $115.8 million and generated $9.9 million of operating cash flow. Long‑term debt remained significant at $221.2 million, including 2028 Convertible Notes and 2029 term loans, and the company continues to invest in its XP‑8121 pipeline and platform partnerships.
Xeris Biopharma Holdings, Inc. reported a strong first quarter of 2026 with total revenue of $83.1 million, up 38% from $60.1 million a year earlier. Net product revenue rose 43% to $82.5 million, driven mainly by Recorlev, whose net revenue increased 95% to $49.8 million, while Gvoke was flat and Keveyis grew 4%.
Gross margin improved to 87% from 85%. Operating expenses increased as the company invested in R&D for XP-8121 and expanded its commercial organization, particularly for Recorlev. Despite higher costs, Xeris generated net income of $2.2 million, compared with a net loss of $9.2 million in the prior-year quarter, and Adjusted EBITDA increased to $15.1 million from $4.4 million.
The company tightened full-year 2026 total revenue guidance to a range of $380 million to $390 million, which it states represents more than 30% growth at the midpoint, and highlighted plans to initiate a Phase 3 trial of XP-8121 later in 2026.
Xeris Biopharma Holdings officer Beth Hecht completed an open-market sale of 16,667 shares of common stock at a weighted average price of $6.2282 per share. After the sale, she directly holds 1,193,173 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.